• The Lancet Gastroenterology & Hepatology in conversation with

  • 著者： The Lancet Group
  • ポッドキャスト

The Lancet Gastroenterology & Hepatology in conversation with

著者： The Lancet Group
無料で聴く

  • サマリー

  • Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.

    A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.
    © 2024 The Lancet Group
    続きを読む 一部表示

あらすじ・解説

Hugh Thomas, Deputy Editor at The Lancet Gastroenterology & Hepatology, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.
© 2024 The Lancet Group
生物科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

    Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
    2024/11/06

    Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    15 分
  • Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease

    Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
    2024/11/01

    Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.

    Read the full articles:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00264-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00233-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    34 分
  • Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer

    Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
    2024/07/31

    Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.

    Read the full article:
    https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgcid=buzzsprout_icw_podcast_generic_langas

    Continue this conversation on social!
    Follow us today at...
    https://twitter.com/thelancet
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    続きを読む 一部表示
    18 分

The Lancet Gastroenterology & Hepatology in conversation withに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。